Pharma & Healthcare
Global Inherited Orphan Blood Disorders Therapeutics Market Research Report 2025
- Dec 02, 25
- ID: 633450
- Pages: 82
- Figures: 86
- Views: 20
This report aims to provide a comprehensive presentation of the global market for Inherited Orphan Blood Disorders Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inherited Orphan Blood Disorders Therapeutics.
The Inherited Orphan Blood Disorders Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inherited Orphan Blood Disorders Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, by Treatment Mechanism and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inherited Orphan Blood Disorders Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Hereditary Hemolytic Diseases
Coagulation Disorders
Metabolic Blood Diseases
Segment by Treatment Mechanism
Gene Replacement Therapy
Gene Editing Therapy
Cell Therapy
Protein Replacement Therapy
Segment by Product Technology
Adeno-associated virus (AAV) Vector Platform
Lentiviral Vector Platform
CRISPR/Cas
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Treatment Mechanism etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inherited Orphan Blood Disorders Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Inherited Orphan Blood Disorders Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inherited Orphan Blood Disorders Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, by Treatment Mechanism and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inherited Orphan Blood Disorders Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Hereditary Hemolytic Diseases
Coagulation Disorders
Metabolic Blood Diseases
Segment by Treatment Mechanism
Gene Replacement Therapy
Gene Editing Therapy
Cell Therapy
Protein Replacement Therapy
Segment by Product Technology
Adeno-associated virus (AAV) Vector Platform
Lentiviral Vector Platform
CRISPR/Cas
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Treatment Mechanism etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inherited Orphan Blood Disorders Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hereditary Hemolytic Diseases
1.2.3 Coagulation Disorders
1.2.4 Metabolic Blood Diseases
1.3 Market by Treatment Mechanism
1.3.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Treatment Mechanism: 2020 VS 2024 VS 2031
1.3.2 Gene Replacement Therapy
1.3.3 Gene Editing Therapy
1.3.4 Cell Therapy
1.3.5 Protein Replacement Therapy
1.4 Market by Product Technology
1.4.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Product Technology: 2020 VS 2024 VS 2031
1.4.2 Adeno-associated virus (AAV) Vector Platform
1.4.3 Lentiviral Vector Platform
1.4.4 CRISPR/Cas
1.5 Market by Application
1.5.1 Global Inherited Orphan Blood Disorders Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Hospital
1.5.3 Retail Pharmacy
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Perspective (2020-2031)
2.2 Global Inherited Orphan Blood Disorders Therapeutics Growth Trends by Region
2.2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Inherited Orphan Blood Disorders Therapeutics Market Dynamics
2.3.1 Inherited Orphan Blood Disorders Therapeutics Industry Trends
2.3.2 Inherited Orphan Blood Disorders Therapeutics Market Drivers
2.3.3 Inherited Orphan Blood Disorders Therapeutics Market Challenges
2.3.4 Inherited Orphan Blood Disorders Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Revenue
3.1.1 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Inherited Orphan Blood Disorders Therapeutics Revenue
3.4 Global Inherited Orphan Blood Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Inherited Orphan Blood Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inherited Orphan Blood Disorders Therapeutics Revenue in 2024
3.5 Global Key Players of Inherited Orphan Blood Disorders Therapeutics Head office and Area Served
3.6 Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Product and Application
3.7 Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Inherited Orphan Blood Disorders Therapeutics Breakdown Data by Type
4.1 Global Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Type (2026-2031)
5 Inherited Orphan Blood Disorders Therapeutics Breakdown Data by Application
5.1 Global Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
6.2 North America Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
6.4 North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
7.2 Europe Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
7.4 Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
9.2 Latin America Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Inherited Orphan Blood Disorders Therapeutics Introduction
11.1.4 Biogen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Inherited Orphan Blood Disorders Therapeutics Introduction
11.2.4 Novartis Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Inherited Orphan Blood Disorders Therapeutics Introduction
11.3.4 Gilead Sciences Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.3.5 Gilead Sciences Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Details
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.4.4 Sarepta Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Inherited Orphan Blood Disorders Therapeutics Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Inherited Orphan Blood Disorders Therapeutics Introduction
11.6.4 Amgen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.6.5 Amgen Recent Development
11.7 Spark Therapeutics
11.7.1 Spark Therapeutics Company Details
11.7.2 Spark Therapeutics Business Overview
11.7.3 Spark Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.7.4 Spark Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.7.5 Spark Therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.8.4 Akcea Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.8.5 Akcea Therapeutics Recent Development
11.9 Sunway Biotech
11.9.1 Sunway Biotech Company Details
11.9.2 Sunway Biotech Business Overview
11.9.3 Sunway Biotech Inherited Orphan Blood Disorders Therapeutics Introduction
11.9.4 Sunway Biotech Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.9.5 Sunway Biotech Recent Development
11.10 SIBIONO
11.10.1 SIBIONO Company Details
11.10.2 SIBIONO Business Overview
11.10.3 SIBIONO Inherited Orphan Blood Disorders Therapeutics Introduction
11.10.4 SIBIONO Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.10.5 SIBIONO Recent Development
11.11 AnGes
11.11.1 AnGes Company Details
11.11.2 AnGes Business Overview
11.11.3 AnGes Inherited Orphan Blood Disorders Therapeutics Introduction
11.11.4 AnGes Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.11.5 AnGes Recent Development
11.12 Orchard Therapeutics
11.12.1 Orchard Therapeutics Company Details
11.12.2 Orchard Therapeutics Business Overview
11.12.3 Orchard Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.12.4 Orchard Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.12.5 Orchard Therapeutics Recent Development
11.13 Human Stem Cells Institute
11.13.1 Human Stem Cells Institute Company Details
11.13.2 Human Stem Cells Institute Business Overview
11.13.3 Human Stem Cells Institute Inherited Orphan Blood Disorders Therapeutics Introduction
11.13.4 Human Stem Cells Institute Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.13.5 Human Stem Cells Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hereditary Hemolytic Diseases
1.2.3 Coagulation Disorders
1.2.4 Metabolic Blood Diseases
1.3 Market by Treatment Mechanism
1.3.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Treatment Mechanism: 2020 VS 2024 VS 2031
1.3.2 Gene Replacement Therapy
1.3.3 Gene Editing Therapy
1.3.4 Cell Therapy
1.3.5 Protein Replacement Therapy
1.4 Market by Product Technology
1.4.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Product Technology: 2020 VS 2024 VS 2031
1.4.2 Adeno-associated virus (AAV) Vector Platform
1.4.3 Lentiviral Vector Platform
1.4.4 CRISPR/Cas
1.5 Market by Application
1.5.1 Global Inherited Orphan Blood Disorders Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Hospital
1.5.3 Retail Pharmacy
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Perspective (2020-2031)
2.2 Global Inherited Orphan Blood Disorders Therapeutics Growth Trends by Region
2.2.1 Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Inherited Orphan Blood Disorders Therapeutics Market Dynamics
2.3.1 Inherited Orphan Blood Disorders Therapeutics Industry Trends
2.3.2 Inherited Orphan Blood Disorders Therapeutics Market Drivers
2.3.3 Inherited Orphan Blood Disorders Therapeutics Market Challenges
2.3.4 Inherited Orphan Blood Disorders Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Revenue
3.1.1 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Top Inherited Orphan Blood Disorders Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Inherited Orphan Blood Disorders Therapeutics Revenue
3.4 Global Inherited Orphan Blood Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Inherited Orphan Blood Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inherited Orphan Blood Disorders Therapeutics Revenue in 2024
3.5 Global Key Players of Inherited Orphan Blood Disorders Therapeutics Head office and Area Served
3.6 Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Product and Application
3.7 Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Inherited Orphan Blood Disorders Therapeutics Breakdown Data by Type
4.1 Global Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Type (2026-2031)
5 Inherited Orphan Blood Disorders Therapeutics Breakdown Data by Application
5.1 Global Inherited Orphan Blood Disorders Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
6.2 North America Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
6.4 North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
7.2 Europe Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
7.4 Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
9.2 Latin America Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Inherited Orphan Blood Disorders Therapeutics Introduction
11.1.4 Biogen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Inherited Orphan Blood Disorders Therapeutics Introduction
11.2.4 Novartis Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Inherited Orphan Blood Disorders Therapeutics Introduction
11.3.4 Gilead Sciences Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.3.5 Gilead Sciences Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Details
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.4.4 Sarepta Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Inherited Orphan Blood Disorders Therapeutics Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Inherited Orphan Blood Disorders Therapeutics Introduction
11.6.4 Amgen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.6.5 Amgen Recent Development
11.7 Spark Therapeutics
11.7.1 Spark Therapeutics Company Details
11.7.2 Spark Therapeutics Business Overview
11.7.3 Spark Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.7.4 Spark Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.7.5 Spark Therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.8.4 Akcea Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.8.5 Akcea Therapeutics Recent Development
11.9 Sunway Biotech
11.9.1 Sunway Biotech Company Details
11.9.2 Sunway Biotech Business Overview
11.9.3 Sunway Biotech Inherited Orphan Blood Disorders Therapeutics Introduction
11.9.4 Sunway Biotech Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.9.5 Sunway Biotech Recent Development
11.10 SIBIONO
11.10.1 SIBIONO Company Details
11.10.2 SIBIONO Business Overview
11.10.3 SIBIONO Inherited Orphan Blood Disorders Therapeutics Introduction
11.10.4 SIBIONO Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.10.5 SIBIONO Recent Development
11.11 AnGes
11.11.1 AnGes Company Details
11.11.2 AnGes Business Overview
11.11.3 AnGes Inherited Orphan Blood Disorders Therapeutics Introduction
11.11.4 AnGes Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.11.5 AnGes Recent Development
11.12 Orchard Therapeutics
11.12.1 Orchard Therapeutics Company Details
11.12.2 Orchard Therapeutics Business Overview
11.12.3 Orchard Therapeutics Inherited Orphan Blood Disorders Therapeutics Introduction
11.12.4 Orchard Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.12.5 Orchard Therapeutics Recent Development
11.13 Human Stem Cells Institute
11.13.1 Human Stem Cells Institute Company Details
11.13.2 Human Stem Cells Institute Business Overview
11.13.3 Human Stem Cells Institute Inherited Orphan Blood Disorders Therapeutics Introduction
11.13.4 Human Stem Cells Institute Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
11.13.5 Human Stem Cells Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hereditary Hemolytic Diseases
Table 3. Key Players of Coagulation Disorders
Table 4. Key Players of Metabolic Blood Diseases
Table 5. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Treatment Mechanism (US$ Million): 2020 VS 2024 VS 2031
Table 6. Key Players of Gene Replacement Therapy
Table 7. Key Players of Gene Editing Therapy
Table 8. Key Players of Cell Therapy
Table 9. Key Players of Protein Replacement Therapy
Table 10. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Product Technology (US$ Million): 2020 VS 2024 VS 2031
Table 11. Key Players of Adeno-associated virus (AAV) Vector Platform
Table 12. Key Players of Lentiviral Vector Platform
Table 13. Key Players of CRISPR/Cas
Table 14. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 17. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2020-2025)
Table 18. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 19. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2026-2031)
Table 20. Inherited Orphan Blood Disorders Therapeutics Market Trends
Table 21. Inherited Orphan Blood Disorders Therapeutics Market Drivers
Table 22. Inherited Orphan Blood Disorders Therapeutics Market Challenges
Table 23. Inherited Orphan Blood Disorders Therapeutics Market Restraints
Table 24. Global Inherited Orphan Blood Disorders Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 25. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Players (2020-2025)
Table 26. Global Top Inherited Orphan Blood Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Orphan Blood Disorders Therapeutics as of 2024)
Table 27. Ranking of Global Top Inherited Orphan Blood Disorders Therapeutics Companies by Revenue (US$ Million) in 2024
Table 28. Global 5 Largest Players Market Share by Inherited Orphan Blood Disorders Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 29. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Headquarters and Area Served
Table 30. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Product and Application
Table 31. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Type (2020-2025)
Table 35. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 36. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Type (2026-2031)
Table 37. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 38. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Application (2020-2025)
Table 39. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 40. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Application (2026-2031)
Table 41. North America Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Europe Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 48. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 49. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 50. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 52. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 53. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 55. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 56. Biogen Company Details
Table 57. Biogen Business Overview
Table 58. Biogen Inherited Orphan Blood Disorders Therapeutics Product
Table 59. Biogen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Biogen Recent Development
Table 61. Novartis Company Details
Table 62. Novartis Business Overview
Table 63. Novartis Inherited Orphan Blood Disorders Therapeutics Product
Table 64. Novartis Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Gilead Sciences Company Details
Table 67. Gilead Sciences Business Overview
Table 68. Gilead Sciences Inherited Orphan Blood Disorders Therapeutics Product
Table 69. Gilead Sciences Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Gilead Sciences Recent Development
Table 71. Sarepta Therapeutics Company Details
Table 72. Sarepta Therapeutics Business Overview
Table 73. Sarepta Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 74. Sarepta Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Sarepta Therapeutics Recent Development
Table 76. Alnylam Pharmaceuticals Company Details
Table 77. Alnylam Pharmaceuticals Business Overview
Table 78. Alnylam Pharmaceuticals Inherited Orphan Blood Disorders Therapeutics Product
Table 79. Alnylam Pharmaceuticals Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Alnylam Pharmaceuticals Recent Development
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen Inherited Orphan Blood Disorders Therapeutics Product
Table 84. Amgen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Amgen Recent Development
Table 86. Spark Therapeutics Company Details
Table 87. Spark Therapeutics Business Overview
Table 88. Spark Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 89. Spark Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Spark Therapeutics Recent Development
Table 91. Akcea Therapeutics Company Details
Table 92. Akcea Therapeutics Business Overview
Table 93. Akcea Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 94. Akcea Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Akcea Therapeutics Recent Development
Table 96. Sunway Biotech Company Details
Table 97. Sunway Biotech Business Overview
Table 98. Sunway Biotech Inherited Orphan Blood Disorders Therapeutics Product
Table 99. Sunway Biotech Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 100. Sunway Biotech Recent Development
Table 101. SIBIONO Company Details
Table 102. SIBIONO Business Overview
Table 103. SIBIONO Inherited Orphan Blood Disorders Therapeutics Product
Table 104. SIBIONO Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 105. SIBIONO Recent Development
Table 106. AnGes Company Details
Table 107. AnGes Business Overview
Table 108. AnGes Inherited Orphan Blood Disorders Therapeutics Product
Table 109. AnGes Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 110. AnGes Recent Development
Table 111. Orchard Therapeutics Company Details
Table 112. Orchard Therapeutics Business Overview
Table 113. Orchard Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 114. Orchard Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 115. Orchard Therapeutics Recent Development
Table 116. Human Stem Cells Institute Company Details
Table 117. Human Stem Cells Institute Business Overview
Table 118. Human Stem Cells Institute Inherited Orphan Blood Disorders Therapeutics Product
Table 119. Human Stem Cells Institute Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 120. Human Stem Cells Institute Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
Table 124. Authors List of This Report
List of Figures
Figure 1. Inherited Orphan Blood Disorders Therapeutics Picture
Figure 2. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Hereditary Hemolytic Diseases Features
Figure 5. Coagulation Disorders Features
Figure 6. Metabolic Blood Diseases Features
Figure 7. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Treatment Mechanism (2020-2031) & (US$ Million)
Figure 8. Gene Replacement Therapy Features
Figure 9. Gene Editing Therapy Features
Figure 10. Cell Therapy Features
Figure 11. Protein Replacement Therapy Features
Figure 12. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Product Technology (2020-2031) & (US$ Million)
Figure 13. Adeno-associated virus (AAV) Vector Platform Features
Figure 14. Lentiviral Vector Platform Features
Figure 15. CRISPR/Cas Features
Figure 16. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 17. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Application: 2024 VS 2031
Figure 18. Hospital Case Studies
Figure 19. Retail Pharmacy Case Studies
Figure 20. Other Case Studies
Figure 21. Inherited Orphan Blood Disorders Therapeutics Report Years Considered
Figure 22. Global Inherited Orphan Blood Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global Inherited Orphan Blood Disorders Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region: 2024 VS 2031
Figure 25. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Players in 2024
Figure 26. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Inherited Orphan Blood Disorders Therapeutics Revenue in 2024
Figure 28. North America Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 30. United States Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 34. Germany Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2020-2031)
Figure 42. China Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 50. Mexico Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 54. Israel Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Biogen Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 58. Novartis Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 59. Gilead Sciences Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 60. Sarepta Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 61. Alnylam Pharmaceuticals Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 62. Amgen Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 63. Spark Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 64. Akcea Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 65. Sunway Biotech Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 66. SIBIONO Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 67. AnGes Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 68. Orchard Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 69. Human Stem Cells Institute Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hereditary Hemolytic Diseases
Table 3. Key Players of Coagulation Disorders
Table 4. Key Players of Metabolic Blood Diseases
Table 5. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Treatment Mechanism (US$ Million): 2020 VS 2024 VS 2031
Table 6. Key Players of Gene Replacement Therapy
Table 7. Key Players of Gene Editing Therapy
Table 8. Key Players of Cell Therapy
Table 9. Key Players of Protein Replacement Therapy
Table 10. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Product Technology (US$ Million): 2020 VS 2024 VS 2031
Table 11. Key Players of Adeno-associated virus (AAV) Vector Platform
Table 12. Key Players of Lentiviral Vector Platform
Table 13. Key Players of CRISPR/Cas
Table 14. Global Inherited Orphan Blood Disorders Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 17. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2020-2025)
Table 18. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 19. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2026-2031)
Table 20. Inherited Orphan Blood Disorders Therapeutics Market Trends
Table 21. Inherited Orphan Blood Disorders Therapeutics Market Drivers
Table 22. Inherited Orphan Blood Disorders Therapeutics Market Challenges
Table 23. Inherited Orphan Blood Disorders Therapeutics Market Restraints
Table 24. Global Inherited Orphan Blood Disorders Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 25. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Players (2020-2025)
Table 26. Global Top Inherited Orphan Blood Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Orphan Blood Disorders Therapeutics as of 2024)
Table 27. Ranking of Global Top Inherited Orphan Blood Disorders Therapeutics Companies by Revenue (US$ Million) in 2024
Table 28. Global 5 Largest Players Market Share by Inherited Orphan Blood Disorders Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 29. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Headquarters and Area Served
Table 30. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Product and Application
Table 31. Global Key Players of Inherited Orphan Blood Disorders Therapeutics, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Type (2020-2025)
Table 35. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 36. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Type (2026-2031)
Table 37. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 38. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Application (2020-2025)
Table 39. Global Inherited Orphan Blood Disorders Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 40. Global Inherited Orphan Blood Disorders Therapeutics Revenue Market Share by Application (2026-2031)
Table 41. North America Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. North America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Europe Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Europe Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 48. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 49. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 50. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 52. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 53. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 55. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 56. Biogen Company Details
Table 57. Biogen Business Overview
Table 58. Biogen Inherited Orphan Blood Disorders Therapeutics Product
Table 59. Biogen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Biogen Recent Development
Table 61. Novartis Company Details
Table 62. Novartis Business Overview
Table 63. Novartis Inherited Orphan Blood Disorders Therapeutics Product
Table 64. Novartis Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Gilead Sciences Company Details
Table 67. Gilead Sciences Business Overview
Table 68. Gilead Sciences Inherited Orphan Blood Disorders Therapeutics Product
Table 69. Gilead Sciences Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Gilead Sciences Recent Development
Table 71. Sarepta Therapeutics Company Details
Table 72. Sarepta Therapeutics Business Overview
Table 73. Sarepta Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 74. Sarepta Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Sarepta Therapeutics Recent Development
Table 76. Alnylam Pharmaceuticals Company Details
Table 77. Alnylam Pharmaceuticals Business Overview
Table 78. Alnylam Pharmaceuticals Inherited Orphan Blood Disorders Therapeutics Product
Table 79. Alnylam Pharmaceuticals Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Alnylam Pharmaceuticals Recent Development
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen Inherited Orphan Blood Disorders Therapeutics Product
Table 84. Amgen Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Amgen Recent Development
Table 86. Spark Therapeutics Company Details
Table 87. Spark Therapeutics Business Overview
Table 88. Spark Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 89. Spark Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Spark Therapeutics Recent Development
Table 91. Akcea Therapeutics Company Details
Table 92. Akcea Therapeutics Business Overview
Table 93. Akcea Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 94. Akcea Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Akcea Therapeutics Recent Development
Table 96. Sunway Biotech Company Details
Table 97. Sunway Biotech Business Overview
Table 98. Sunway Biotech Inherited Orphan Blood Disorders Therapeutics Product
Table 99. Sunway Biotech Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 100. Sunway Biotech Recent Development
Table 101. SIBIONO Company Details
Table 102. SIBIONO Business Overview
Table 103. SIBIONO Inherited Orphan Blood Disorders Therapeutics Product
Table 104. SIBIONO Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 105. SIBIONO Recent Development
Table 106. AnGes Company Details
Table 107. AnGes Business Overview
Table 108. AnGes Inherited Orphan Blood Disorders Therapeutics Product
Table 109. AnGes Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 110. AnGes Recent Development
Table 111. Orchard Therapeutics Company Details
Table 112. Orchard Therapeutics Business Overview
Table 113. Orchard Therapeutics Inherited Orphan Blood Disorders Therapeutics Product
Table 114. Orchard Therapeutics Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 115. Orchard Therapeutics Recent Development
Table 116. Human Stem Cells Institute Company Details
Table 117. Human Stem Cells Institute Business Overview
Table 118. Human Stem Cells Institute Inherited Orphan Blood Disorders Therapeutics Product
Table 119. Human Stem Cells Institute Revenue in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025) & (US$ Million)
Table 120. Human Stem Cells Institute Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
Table 124. Authors List of This Report
List of Figures
Figure 1. Inherited Orphan Blood Disorders Therapeutics Picture
Figure 2. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Hereditary Hemolytic Diseases Features
Figure 5. Coagulation Disorders Features
Figure 6. Metabolic Blood Diseases Features
Figure 7. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Treatment Mechanism (2020-2031) & (US$ Million)
Figure 8. Gene Replacement Therapy Features
Figure 9. Gene Editing Therapy Features
Figure 10. Cell Therapy Features
Figure 11. Protein Replacement Therapy Features
Figure 12. Global Inherited Orphan Blood Disorders Therapeutics Market Size Comparison by Product Technology (2020-2031) & (US$ Million)
Figure 13. Adeno-associated virus (AAV) Vector Platform Features
Figure 14. Lentiviral Vector Platform Features
Figure 15. CRISPR/Cas Features
Figure 16. Global Inherited Orphan Blood Disorders Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 17. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Application: 2024 VS 2031
Figure 18. Hospital Case Studies
Figure 19. Retail Pharmacy Case Studies
Figure 20. Other Case Studies
Figure 21. Inherited Orphan Blood Disorders Therapeutics Report Years Considered
Figure 22. Global Inherited Orphan Blood Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global Inherited Orphan Blood Disorders Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Region: 2024 VS 2031
Figure 25. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Players in 2024
Figure 26. Global Inherited Orphan Blood Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Inherited Orphan Blood Disorders Therapeutics Revenue in 2024
Figure 28. North America Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 30. United States Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 34. Germany Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Inherited Orphan Blood Disorders Therapeutics Market Share by Region (2020-2031)
Figure 42. China Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 50. Mexico Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Inherited Orphan Blood Disorders Therapeutics Market Share by Country (2020-2031)
Figure 54. Israel Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE Inherited Orphan Blood Disorders Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Biogen Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 58. Novartis Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 59. Gilead Sciences Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 60. Sarepta Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 61. Alnylam Pharmaceuticals Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 62. Amgen Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 63. Spark Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 64. Akcea Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 65. Sunway Biotech Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 66. SIBIONO Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 67. AnGes Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 68. Orchard Therapeutics Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 69. Human Stem Cells Institute Revenue Growth Rate in Inherited Orphan Blood Disorders Therapeutics Business (2020-2025)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232